Advertisement

Bonus Episode: Targeted Topicals in Action: AD Patient Success Stories

In this roundtable discussion, Moderator Christopher Bunick, MD, PhD, an Associate Professor of Dermatology at Yale University and Director of The Bunick Lab at Yale in New Haven, CT, talks with Terry Faleye, MPAS, PA-C, a Physician Associate in Kingswood, TX, Andrew Mastro, MS, PA-C, a Physician Assistant in Chicago, IL, and Lisa Swanson, MD, a Pediatric Dermatologist in Boise, ID, about the growing role that advanced topical therapies such as ruxolitinib (Opzelura, Incyte) can, and should, play in atopic dermatitis (AD).

In this seven-episode arc, experts weigh in on ideal candidates for today’s targeted topicals, best practices for counseling patients and caregivers on their safety, the importance of combining clinician- and patient-reported outcomes that capture the full impact of the disease on quality of life, plus other key considerations when treating AD.

Advertisement

Digital Edition

MORE FROM THIS SERIES
Episode 1: What Today's AD Patients Want (and Don't Want)
Episode 2: Targeted Topical Therapy in AD: Who, When, and Why
Episode 3: Topical JAK Inhibitors: In Focus and In Practice
Episode 4: First, Do No Harm: Discussing Topical Treatment Safety With AD Patients and Caregivers
Episode 5: Managing Common Side Effects of Newer Targeted Topicals in AD
Episode 6: What AD Patients and Their Caregivers Really Want to Know
Episode 7: Rapid Fire Pearls on Treating AD With Advanced Topical Therapies
Current Episode—BONUS EPISODE: Targeted Topicals in Action: AD Patient Success Stories